PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 06: PIPELINE LANDSCAPE PART 07: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 08: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 09: MARKET SEGMENTATION BY APPLICATION • Segmentation by application • Comparison by application • Oncology – Market size and forecast 2017-2022 • Cardiovascular – Market size and forecast 2017-2022 • Anti-infectives – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by application PART 10: MARKET SEGMENTATION BY SOURCE • Invertebrate • Vertebrate • Others PART 11: CUSTOMER LANDSCAPE PART 12: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Key leading countries • Market opportunity PART 13: DECISION FRAMEWORK PART 14: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 15: MARKET TRENDS • Marine peptides as anti-infectives • Research for anti-inflammatory compounds from marine sources PART 16: VENDOR LANDSCAPE • Overview • Landscape disruption PART 17: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • GlaxoSmithKline • Jazz Pharmaceuticals • PharmaMar • Seattle Genetics PART 18: APPENDIX • List of abbreviations Exhibit 01: Marine pharmaceutical: An overview Exhibit 02: Parent market Exhibit 03: Global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Pipeline molecules: An overview Exhibit 07: Key clinical trials Exhibit 08: Market definition - Inclusions and exclusions checklist Exhibit 09: Market size 2017 Exhibit 10: Validation techniques employed for market sizing 2017 Exhibit 11: Global marine pharmaceuticals– Market size and forecast 2017-2022 ($ millions) Exhibit 12: Global marine pharmaceuticals – Year-over-year growth 2018-2022 (%) Exhibit 13: Five forces analysis 2017 Exhibit 14: Five forces analysis 2022 Exhibit 15: Bargaining power of buyers Exhibit 16: Bargaining power of suppliers Exhibit 17: Threat of new entrants Exhibit 18: Threat of substitutes Exhibit 19: Threat of rivalry Exhibit 20: Market condition - Five forces 2017 Exhibit 21: Application – Market share 2017-2022 (%) Exhibit 22: Comparison by application Exhibit 23: Oncology – Market size and forecast 2017-2022 ($ millions) Exhibit 24: Oncology – Year-over-year growth 2018-2022 (%) Exhibit 25: Cardiovascular – Market size and forecast 2017-2022 ($ millions) Exhibit 26: Cardiovascular – Year-over-year growth 2018-2022 (%) Exhibit 27: Anti-infectives – Market size and forecast 2017-2022 ($ millions) Exhibit 28: Anti-infectives – Year-over-year growth 2018-2022 (%) Exhibit 29: Others – Market size and forecast 2017-2022 ($ millions) Exhibit 30: Others – Year-over-year growth 2018-2022 (%) Exhibit 31: Market opportunity by application Exhibit 32: Customer landscape Exhibit 33: Global marine pharmaceuticals – Market share by geography 2017-2022 (%) Exhibit 34: Regional comparison Exhibit 35: Americas – Market size and forecast 2017-2022 ($ millions) Exhibit 36: Americas – Year-over-year growth 2018-2022 (%) Exhibit 37: EMEA – Market size and forecast 2017-2022 ($ millions) Exhibit 38: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 39: APAC – Market size and forecast 2017-2022 ($ millions) Exhibit 40: APAC – Year-over-year growth 2018-2022 (%) Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: GlaxoSmithKline – Overview Exhibit 49: GlaxoSmithKline – Business segments Exhibit 50: GlaxoSmithKline – Organizational developments Exhibit 52: GlaxoSmithKline – Geographic focus Exhibit 53: GlaxoSmithKline – Segment focus Exhibit 54: GlaxoSmithKline – Key offerings Exhibit 55: GlaxoSmithKline – Key customers Exhibit 56: Jazz Pharmaceuticals – Overview Exhibit 57: Jazz Pharmaceuticals – Organizational developments Exhibit 58: Jazz Pharmaceuticals – Geographic focus Exhibit 59: Jazz Pharmaceuticals – Key offerings Exhibit 60: GlaxoSmithKline – Key customers Exhibit 61: PharmaMar – Overview Exhibit 62: PharmaMar – Business segments Exhibit 63: PharmaMar – Organizational developments Exhibit 64: PharmaMar – Geographic focus Exhibit 65: PharmaMar – Segment focus Exhibit 66: PharmaMar – Key offerings Exhibit 67: PharmaMar – Key customers Exhibit 68: Seattle Genetics – Overview Exhibit 69: Seattle Genetics – Business segments Exhibit 70: Seattle Genetics – Organizational developments Exhibit 71: Seattle Genetics – Geographic focus Exhibit 72: Seattle Genetics – Segment focus Exhibit 73: Seattle Genetics – Key offerings Exhibit 74: Seattle Genetics – Key customers

GlaxoSmithKline, Jazz Pharmaceuticals, PharmaMar, and Seattle Genetics.